Musculoskeletal Diseases

All Conditions

Neoplasms

Symptoms and General Pathology

Behaviors and Mental Disorders

Osteoarthritis

Carcinoma

Carcinoma, Squamous Cell

Squamous Cell Carcinoma of Head and Neck

Recurrence

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Neoplasms, Squamous Cell

Head and Neck Neoplasms

Quality of Life

Intensity Modulated Radiation Therapy (IMRT)

Radiation with 6 MV photons to dose of 70Gy/ 35#/ 7 weeks

3 Dimensional Radiation Therapy

IMRT with 6 MV photons to a dose of 66Gy/30#/ 6 weeks

Intensity Modulated Radiation Therapy

Sarbani Ghosh-Laskar, MD

Ketayun Dinshaw, FRCR

Head \& Neck squamous cell carcinomas are the commonest cancers afflicting the developing countries. Traditionally surgery or radiotherapy alone in the early stages and surgery with postoperative radiotherapy in advanced stages have been the mainstay of treatment. Of late there has been a paradigm shift in the management of these cancers, particularly those of the oropharynx and laryngopharynx, where chemoradiation has been advocated as part of organ preservation protocol with good outcomes. Conventional radiotherapy involves the use of 2 or 3 field technique with or without compensators to encompass the volume at risk to radical doses of 66-70 Gy typically needed to sterilize gross disease. This strategy however is associated with considerable acute morbidity (mucositis, dysphagia, dermatitis) and debilitating late toxicity (xerostomia). Three dimensional conformal radiation therapy (3D-CRT) and intensity modulated radiation therapy (IMRT) have the potential to improve the dose distribution, with increased doses to the target volumes and reduced doses to surrounding normal structures, thereby improving the therapeutic ratio.

1.0 Introduction: Head \& Neck squamous cell carcinomas are the commonest cancers afflicting the developing countries. Traditionally surgery or radiotherapy alone in the early stages and surgery with postoperative radiotherapy in advanced stages have been the mainstay of treatment. Of late there has been a paradigm shift in the management of these cancers, particularly those of the oropharynx and laryngopharynx, where chemoradiation has been advocated as part of organ preservation protocol with good outcomes. Conventional radiotherapy involves the use of 2 or 3 field technique with or without compensators to encompass the volume at risk to radical doses of 66-70 Gy typically needed to sterilize gross disease. This strategy however is associated with considerable acute morbidity (mucositis, dysphagia, dermatitis) and debilitating late toxicity (xerostomia). Three dimensional conformal radiation therapy (3D-CRT) and intensity modulated radiation therapy (IMRT) have the potential to improve the dose distribution, with increased doses to the target volumes and reduced doses to surrounding normal structures, thereby improving the therapeutic ratio.

2.0 Objectives: 2.1 To compare the major salivary gland sparing by 3-D CRT vis-à-vis IMRT and assess the adequacy of target volume coverage with these conformal techniques.

2.2 To determine the pattern of local and loco-regional recurrence. 2.3 To determine Disease Free Survival (DFS) \& Overall Survival (OAS) 2.4 To study the quality of life of these patients 2.5 To assess the reduction in dose with IMRT to the normal larynx \& normal pharyngeal constrictors in oropharyngeal cancers, uninvolved oral mucosa and middle \& inner ear apparatus in both oropharyngeal \& laryngopharyngeal cancers

3.0 Patient Selection: 3.1 Eligibility 3.1.1 Biopsy proven squamous cell carcinoma of the oropharynx or laryngopharynx.

3.1.2. AJCC stage T1-3, NO-2b, MO patients with pre-treatment tumor measurements clinically as well as on CT/MRI scans. 3.1.3 Surgery of the primary tumor limited to excisional or incisional biopsy. 3.1.4 No form of neck dissection for nodal metastases. 3.1.5 KPS \> 60 (see appendix I). 3.1.6 Age \> 18 and \< 65 years. 3.1.7 No prior history of therapeutic irradiation. 3.1.8 Patient willing and reliable for follow-up. 3.1.9 Patient's nutritional \& physical condition compatible with planned therapy.

3.1.10 Signed study specific consent form (see Appendix II). 3.2 Ineligibility criteria: 3.2.1 Evidence of distant metastases. 3.2.2 Previous therapeutic irradiation for head \& neck cancer or any other invasive cancer other than squamous or basal cell carcinoma of the skin. 3.2.3 History of prior malignancy. 3.2.4 Prophylactic use of amifostine or pilocarpine. 3.2.5 Active untreated infection like tuberculosis, which preclude the use of systemic chemotherapy or would interfere with completion of treatment. 3.2.6 Any histopathology other than Squamous Carcinoma. 3.2.7 Primary nasopharyngeal carcinoma. 3.2.8 Age \< 18 or \> 65 years. 3.2.9 Pregnancy or lactating women. 4.0 Pre-treatment evaluation: 4.1 All patients required to complete the following prior to start of therapy: 4.1.1 Complete history and physical examination including weight and height. 4.1.2. Complete diagrammatic and descriptive documentation of the extent of disease, both primary and regional following appropriate endoscopic procedures. 4.1.3 Complete dental and nutritional evaluation. All dental repair to be done at least one week prior to starting therapy. 4.1.4 Completion of the following laboratory investigations: CBC, LFT, RFT, TFT, baseline speech assessment and audiometric assessment. 4.1.5 Completion of the following radiological investigations: CXR, CT/MRI of the head \& neck with volumetric assessments, Planning scan with contrast (unless otherwise contraindicated) with 3mm contiguous slices in appropriate immobilization systems. A PET scan or a CT-PET hybrid scan may be done at the discretion of the treating physician (Appendix III). Bone scan and liver scan as per clinical indication.

4.1.6 Salivary scintigraphy for the parotid glands. 4.1.7 A baseline QOL questionnaire (Appendix IV) will be filled in for each patient.

5.0 Radiation therapy: 5.1 Treatment planning, imaging \& localization requirements. 5.1.1 Immobilization: In supine position with a customized thermoplastic device.

5.1.2 Planning scan: Contrast enhanced planning CT scan of the area of interest with 3mm slices on CT-simulator that is networked to the treatment planning system (Cadplan).

5.1.3 Target delineation: Planning target volumes (GTV and CTV) and organ at risk volumes (spinal cord and both the parotids) to be contoured on each slice. Other organs such as uninvolved oral mucosa, middle \& inner ear and normal larynx \& pharyngeal constrictors in oropharyngeal cancers also to be contoured on each slice. An isometric margin of 5mm to be provided to the CTV for final PTV and 3mm to organs at risk for planning organ at risk volume (PORV). The GTV will include only the primary and involved neck nodes. The delineation of the various volumes will be as per consensus guidelines. The priorities and constraints for IMRT plan will also be decided on a case to case basis (see appendix V for details).

5.1.4 Prescription: The goal of the treatment plan would be to encompass the PTV subclinical disease with a dose of 60-54 Gy conventional fractionation equivalent and the GTV with 70 Gy equivalent while sparing as much of the aforesaid critical structures as possible without compromising on the GTV. Primary target (gross disease with margins) dose will be 70 Gy conventional fractionation equivalent (70 Gy/35#/7 weeks with 3-D CRT ad 66 Gy/30#/6 weeks with IMRT). The secondary target (sub-clinical disease) dose will be 50-54 Gy conventional fractionation equivalent (50-54 Gy/28-30#/5.5-6 weeks with 3-D CRT and 54 Gy/30#/6 weeks with IMRT). An optional secondary target area may be defines as area of high risk disease (e.g. first echelon nodes). This shall receive 60 Gy/30#/6 weeks with both 3-D CRT and IMRT.

The maximum permissible point doses to the spinal cord will be limited to 40 Gy. All patients to be planned with both 3-D CRT as well as IMRT, irrespective of the final treatment protocol. 3-D CRT planning to be done on Cadplan/Eclipse (Varian, USA) using multileaf collimators (MLCs) for beam shaping. IMRT planning to be done using Helios inverse planning module of Cadplan/Eclipse. Treatment to be delivered on a Varian LINAC (2100 CD or 6 Ex) using dynamic MLCs (sliding window technique).

5.1.5 Plan evaluation: Comparative evaluation of the bease 3-D CRT and IMRT plan for the individual patient to be done. Cumulative dose volume histograms (DVHs) to be computed for PTV and each PORV to assist in plan evaluation. Plans to be compared with respect to conformal avoidance of organs at risk, conformity index, homogeneity index and DVHs. An in detail evaluation of the quality assurance (Appendix VI) and dosimetric methods involved in the procedure would also be carried out and will be correlated with final outcome.

6.0 Other therapy: 6.1 Chemotherapy: Concurrent platinum based chemotherapy to be considered for all patients with T3 or N+ disease.

6.2 Cytoprotectors: Use of amifostine or pilocarpine is not allowed. 7.0 Patient assessments: 7.1 Patients assessments table (see Appendix VII for details). 7.2 Evaluation 7.2.1 Every follow up visit: All patients require to follow up 6weeks and 12 weeks from end of radiotherapy, Thereafter follow up visits would be scheduled three monthly for the first two years and annually thereafter. Routine head \& neck examination, including endoscopic examination will be performed at the first follow-up and thereafter as and when needed, performance status, weight, toxicity and QOL documentation will be carried out at each follow-up. Salivary scintigraphy, swallowing status, speech assessment, thyroid function test and audiometry will be done at first follow-up post treatment and six monthly thereafter. Follow-up PET scan to be done at the discretion of the treating physician. Dental care to be provided as and when needed.

7.2.2 Other studies: CXR for persistent cough, hemoptysis or chest pain; skeletal survey or bone scan in case of any bone pains and biopsy of any suspicious lesion in the upper aero-digestive tract.

7.2.3 Objective response criteria (see Appendix VIII). 7.3 Criteria for removal from treatment 7.3.1 Progression of disease while on treatment 7.3.2 Withdrawal of consent by patient 7.3.3 Severe radiation morbidity resulting in a break of 2 weeks or more. 8.0 Data Collection: 8.1 Summary of data submission ITEM DUE Demographic form Within 2 weeks of study entry Initial Evaluation form 1 week before RT start Diagnostic Pathology Report Before RT start Baseline QOL assessment 1 week before start of treatment Radiotherapy form Within 1 week of end of RT Adverse Event form (see appendix IX for details) Initial follow-up form At 6 weeks from end of RT Follow-up forms At 3, 6 \& 12 Months from end of RT Long term follow-up forms Yearly after 5 years Autopsy report If needed

8.2 Summary of RT QA requirements (see Appendix VI for details): Preliminary Dosimetric Information Within 1 week of start of RT Simulation \& Port films Every week Final Dosimetric Information Within 1 week of end of RT

Hard copy of isodoses and DVH for total plan including any charges

9.0 Statistical consideration: 9.1.1 The primary end point is acute salivary gland toxicity (\> = Gr 2) as per the RTOG toxicity criteria (see Appendix X \& XI). This is also to be assessed by salivary scintigraphy and subjectively by patient self-assessment. As a surrogate dose volume histogram shall be used for assessment for major salivary gland sparing.

9.1.2 Secondary endpoints include: a) Local \& Loco-regional control b) DFS \& c) OAS 9.2 Patient accrual, sample size \& analysis: 60 patients. 9.2.1 Approximately 85% of patients with conventional techniques or 3-D CRT would develop acute salivary gland toxicity of grade 2 or more. With IMRT, it is hypothesized that this could be reduced to 50%. The total number of patients needed would be fifty-four assuming alpha error 0.05 and beta error 0.20 (one tailed test). The projected 3 year locoregional control rate for this group is 70%. Ensuring that the salivary gland sparing should not be at the expense of loco-regional control, the upper limit for locoregional failure rate is set at 45% as per Fleming's one step multiple testing procedure. In case this is exceeded anytime during the interim analysis, the entire protocol shall be re-examined.

9.2.2 Sixty patients to be accrued over a 24 month period from date of start 9.2.3 Interim analysis of toxicity and accrual data planned every six months. Initial results of treatment to be reported when all patients have completed at least 6 months on follow-up. Final results to be reported at a minimum of 2 year follow-up on all patients.

Study of 3-Dimensional Conformal Radiotherapy (3D-CRT) Versus Intensity Modulated Radiotherapy (IMRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)

Phase II Study of 3-Dimensional Conformal Radiotherapy (3D-CRT) vs Intensity Modulated Radiotherapy (IMRT) for Squamous Cell Carcinoma of the Head and Neck (HNSCC)

Tata Memorial Hospital

Sarbani Ghosh-Laskar

Respiratory Tract (Lung and Bronchial) Diseases

Ear, Nose, and Throat Diseases

Rare Diseases

Laryngeal Diseases

Laryngeal Cancer

this patients randomised to this arm will be planned by 3DCRT and during treatment setup error will be identified and corrected by weekly EPID if error \>3mm.Weekly CBCT will be done for this arm to note the setup error but will not be corrected.

The patients randomised to this arm will be planned by 3DCRT and set up error during RT will be verified by CBCT and error corrected if \>3mm.Weekly EPID will be done for setup error documentation but no correction based on EPID in this arm.

Set up error verification and correction by EPID

EPID Verification

Setup error verification and correction by CBCT

CBCT verification

BIDHU K MOHANTI, MD

This study aims to study the impact image guided radiotherapy with Cone beam CT will have on the outcomes(toxicities and response) of head and neck cancer when compared to 3D conformal radiotherapy without CBCT based setup error verification.Also,the various dosimetric variations in Adaptive RT will be studied.

Aims and Objectives

1. To assess the patient's radiation dose planning for GTV, CTV and PTV for primary and nodal regions and derive comparison between IGRT and 3D-CRT.
2. To assess the dosimetric variation in different phases of adaptive RT due to changes in tumor shape and volume during the course of entire treatment in IGRT arm in head and neck cancer patients.
3. To evaluate the optimal setup correction methodology using planar (EPID) and volumetric images (CBCT) in HNSCC between 3D-CRT and IGRT treatment delivery respectively.
4. To compare the early tumour response and acute and chronic radiation morbidities between IGRT and 3D-CRT.

Evaluation of 3DCRT Versus IGRT and Analysis of Early Response in Head and Neck Cancer.

Randomised Clinical Phase III Study of Radiotherapy Dose, Volume Evaluation for 3DCRT Versus IGRT and Analysis of Early Response in Head and Neck Squamous Cell Carcinoma

The advent of CBCT has increased the verification of Radiation treatment delivery but whether it leads to significant change in tumour response or toxicities when compared to 3D Conformal Radiotherapy without CBCT verification is not known.This study will give insights into this question.

Assessment will be done by RTOG scoring criteria

All India Institute of Medical Sciences, New Delhi

DR.SUJITH KUMAR MULLAPALLY

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Antineoplastic Agents

All Drugs and Chemicals

Gemcitabine

Nedaplatin

Antimetabolites

Gemcitabine(1000mg/m2)，Nedaplatin(60mg/m2),BAI, Day 1/4weeks. 4weeks per cycle. Tumor assessment will be perforemd after 2 cycles. if no PD, patient will be treated with 3DCRTfor 1 month. for patient PD after 3DCRT, complete the study. patient no PD after 3DCRT will receive 2 cycle of chemo with Gemcitabine. Nedaplatin.

then patient will be followed for 1 year..

Gemcitabine 100mg/m2, D1 \& D8 every 4 weeks Nedaplatin 75mg/m2, D1 every 4 weeks. every 4 weeks per cycle. Tumor assessment will be performed after 2 cycles. if no PD, patient will be treated with 3DCRT for 1 month.

for patient PD after 3DCRT, complete the study. patient no PD after 3DCRT will receive 2 cycle of chemo with Gemcitabine. Nedaplatin.

then patient will be followed for 1 year.

Gemcitabine, Injection, 1000mg/m2, D1 \& D7/ 4weeks/cycle, 2 cycles Nedaplatin, Injection, 75mg/m2, d1/4weeks/cycle, 2 cycles.

Gemcitabine, Nedaplatin, iV

non-PD Patient will be treated with 3DCRT after 2 cycles of chemo.

3DCRT

Drug: Gemcitabine, Nedaplatin, iV

Gemcitabine, Injection, 1000mg/m2, D1/4weeks/cycle, 2 cycles Nedaplatin, Injection, 75mg/m2, d1/4weeks/cycle, 2 cycles. BAI

Gemcitabine，Nedaplatin, BAI

YI LI

Yi Li

The purpose of this study is to investigate the efficacy of BAI Plus 3DCRT in local advanced NSCLC.

Study to Investigate Bronchial Arterrial Infusing (BAI) Plus Three-dimensional Conformal Radiotherapy (3DCRT) in Local Advanced Non-small Cell Lung Cancer (NSCLC)

A Randomized, Two Arm Study to Investigate Bronchial Arterrial Infusing (BAI) Plus Three-dimensional Conformal Radiotherapy (3DCRT) in Local Advanced Non-small Cell Lung Cancer (NSCLC)

Regular tumour assessments (based on RECIST criteria) for determining disease response and progression using CT and MRI scans, and overall survival.The primary efficacy variable is progression free survival (PFS), defined as the time between randomisation and the date of first documented disease progression or death from any cause, whichever comes first. Disease progression is defined according to the RECIST criteria.

after Progressive Disease, patient will be contact every 3 month for the survival information.

Regular tumour assessments (based on RECIST criteria) for determining disease response and progression using CT and MRI scans.Time to Progression (TTP) is defined as the time between randomisation and the date of the first documented disease progression.

Third Military Medical University

Medulloblastoma

Glioma

Neoplasms, Neuroepithelial

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms, Nerve Tissue

Neuroepithelioma

This arm will be planned by 3DCRT to the treatment of the Medulloblastoma

This arm will be planned by TOMO to the treatment of the Medulloblastoma

Patients with Medulloblastoma receiving Tomotherapy

Tomotherapy HD

Patients with Medulloblastoma receiving Three-Dimensional Conformal Radiation Therapy

chuanying zhu, MD

Chuanying zhu, MD

Mawei Jiang, MD

mawei jiang, MD

The aim of the study was to improve local control and long-term survival in children with medulloblastoma, reduce the side effects of treatment and improve quality of life.

The technical advantages of Tomotherapy HD in the radiotherapy of children medulloblastoma (advantages in clinical operation and physics) were transformed into clinical advantages, and the possible mechanisms were explored.

Study of Tomotherapy HD in Medulloblastoma

Changes in quality of life were assessed by EORTC QLQ-C30

from the first day of therapy to the date of disease progression or death from any cause, whichever was first (according the criterion of RECIST 1.1 ).

from the first day of therapy to death or last follow-up

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Digestive System Diseases

Esophageal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Esophageal Diseases

Esophageal Cancer

Three-dimensional conformal radiotherapy (3DCRT)

Zefen Xiao, MD

Wenyang Liu, MD

Radiotherapy is one of the main treatments for locally advanced esophageal carcinoma (EC). The accuracy of the existing imaging methods in diagnosing and predicting therapeutic efficacy is disappointing, which increases the difficulty in clinical decision-making. In this study, based on a continuous cohort of EC treated with radiotherapy, the clinical and pathological factors of the patients are used to classify them into the appropriate therapeutic group. By multiple liquid biopsy technologies, combining with radiomics, we intend to construct prediction models of prognosis, therapeutic effect and toxicity. The aim of this RWS is to provide appropriate individualized regimen, further optimize the treatment mode based on precision radiotherapy and improve the outcome and quality of life of EC patients.

Radiotherapy is one of the main treatments for locally advanced esophageal squamous cell carcinoma (ESCC). The guidelines recommend neoadjuvant concurrent chemoradiotherapy plus surgery for resectable or potentially resectable patients; for unresectable patients, definitive chemoradiotherapy is the standard treatment. However, due to the complexity of the biological behavior of esophageal cancer (EC) and individual differences, fully complying with guideline recommendations in clinical practice is difficult and idealized. The results of prospective clinical trials are difficult to meet the demand of clinical diagnosis and treatment, thus, carrying out high-quality real-world study (RWS) is necessary.

Three-dimensional conformal radiotherapy (3DCRT) for unresectable EC yields 5-year OS rates of 34%-45.6%, which is an improvement over the rates reported in the RTOG 85-01 and 94-05 studies. Even so, there is still room for improvement of local control rate and overall survival. The accuracy of the existing imaging methods \[computed tomography (CT), magnetic resonance imaging (MRI), endoscopic ultrasonography (EUS), endoscopic ultrasonography (EUS), as well as positron-emission tomography (PET)-CT, etc.\] in diagnosing and predicting therapeutic efficacy is disappointing, which increases the difficulty in clinical decision-making. It is worthy to investigate an appropriate individualized radiation regimen based on different treatment sensitivity.

In this study, based on a continuous cohort of EC treated with radiotherapy, the clinical and pathological factors of the patients are used to classify them into the appropriate therapeutic group. Collect the blood and saliva samples before, during and after radiotherapy; the remaining diagnostic biopsy tissue samples. By using multiple liquid biopsy technologies \[microbial flora, circulating tumor DNA (ctDNA), genome, RNA, and immunophenotype, ect.\], combining with radiomics, construct prediction models of prognosis, therapeutic effect and toxicity. The aim of this RWS is to provide appropriate individualized regimen, further optimize the treatment mode based on precision radiotherapy and improve the outcome and quality of life of EC patients.

The blood and saliva samples before, during and after radiotherapy; the remaining diagnostic biopsy tissue samples.

Real-world Study on Comprehensive Treatment of Esophageal Cancer Based on Precision Radiotherapy

potential biomarkers in tumor samples and blood samples

measurement basing on EORTC (Quality of life of patients with oesophageal cancer) QLQ-C30 tables

measurement basing on EORTC (Quality of life of patients with oesophageal cancer) QLQ-OES18 tables

Zefen Xiao

Professor

Skin and Connective Tissue Diseases

Breast Neoplasms

conventional 3-dimensional conformal radiotherapy on the breast, 50.4 Gy/28 fx and tumor bed boost, 9 Gy/5 fx will be irradiated for 6.5 weeks.

Intensity-modulated radiotherapy (IMRT) with simultaneous integrated boost (SIB) on the whole breast, 50.4 Gy/28 fx and tumor bed, 57.4 Gy/28 fx will be irradiated for 5.5 weeks.

Unlike 3DCRT, concomittant boost technique is used in the IMRT arm.

Jong Hoon Lee, MD

Yukang Kwak, MD

It has been not clinically determined whether TomoDirect was dosimetrically better than 3D-CRT for Asian patients with early breast cancer. Therefore, the objective of this study was to compare dosimetric parameters of TomoDirect and 3D-CRT in early breast cancer patients of an Asian cohort.

In breast cancer patients, helical TomoTherapy is not a suitable option since the gantry continuously rotates around the patient, and this technique can deliver low dose radiation to lungs that is associated with an occurrence of radiation pneumonitis. To avoid this inefficiency of beam usage, a TomoDirect option using static gantry positions combined with simultaneous couch translation and dynamic collimator modulation has been developed. In a pilot study, TomoDirect seemed particularly well suited for postoperative irradiation in breast cancer patients. TomoDirect achieved an optimal target volume coverage and coincident adequate normal tissue sparing in a dosimetric study. Clinical studies of TomoDirect in breast cancer patients are scarce and have been assessed only in small and retrospective series. Thus, we undertook a prospective study on the technical feasibility and toxicity of TomoDirect in breast cancer patients who received postoperative radiotherapy.

3DCRT vs. IMRT in Early Breast Cancer

Postoperative Radiotherapy With Intensity-modulated Radiation Therapy (IMRT) Using Simultaneous Integrated Boost Versus 3-dimensional Conformal Radiotherapy (3D-CRT) in Early Breast Cancer: a Prospective Randomized Trial

Acute toxicity within 3 months after radiotherpy and late toxicity thereafter up to 3 years will be followed up by physicians. Adverse effects of radiotherapy were assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0). Incidence of toxicity grade ≥ 2 was recorded.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Study of 3-Dimensional Conformal Radiotherapy (3D-CRT) Versus Intensity Modulated Radiotherapy (IMRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)	NCT00652613	Squamous Cell C...	3 Dimensional R... Intensity Modul...	18 Years - 65 Years	Tata Memorial Hospital
Evaluation of 3DCRT Versus IGRT and Analysis of Early Response in Head and Neck Cancer.	NCT01124409	HEAD AND NECK C... CARCINOMA OROPH... CARCINOMA PYRIF... CARCINOMA LARYN...	EPID Verificati... CBCT verificati...	18 Years - 65 Years	All India Institute of Medical Sciences, New Delhi
Study to Investigate Bronchial Arterrial Infusing (BAI) Plus Three-dimensional Conformal Radiotherapy (3DCRT) in Local Advanced Non-small Cell Lung Cancer (NSCLC)	NCT01201044	Non-small Cell ...	Gemcitabine, Ne... 3DCRT 3DCRT Gemcitabine，Ned...	18 Years - 70 Years	Third Military Medical University
Study of Tomotherapy HD in Medulloblastoma	NCT03675230	Medulloblastoma	Tomotherapy HD 3DCRT	3 Years - 12 Years	Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Real-world Study on Comprehensive Treatment of Esophageal Cancer Based on Precision Radiotherapy	NCT05543057	Esophageal Canc...	3DCRT	18 Years - 90 Years	ChineseAMS
Study to Investigate Bronchial Arterrial Infusing (BAI) Plus Three-dimensional Conformal Radiotherapy (3DCRT) in Local Advanced Non-small Cell Lung Cancer (NSCLC)	NCT01201044	Non-small Cell ...	Gemcitabine, Ne... 3DCRT 3DCRT Gemcitabine，Ned...	18 Years - 70 Years	Third Military Medical University
3DCRT vs. IMRT in Early Breast Cancer	NCT02440191	Radiation Toxic...	3DCRT	20 Years - 75 Years	Seoul St. Mary's Hospital
Real-world Study on Comprehensive Treatment of Esophageal Cancer Based on Precision Radiotherapy	NCT05543057	Esophageal Canc...	3DCRT	18 Years - 90 Years	ChineseAMS
3DCRT vs. IMRT in Early Breast Cancer	NCT02440191	Radiation Toxic...	3DCRT	20 Years - 75 Years	Seoul St. Mary's Hospital

Spots Global Cancer Trial Database for 3dcrt

Every month we try and update this database with for 3dcrt cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for 3dcrt

Every month we try and update this database with for 3dcrt cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for 3dcrt cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.